Wen-Hung CHUNG MD

Pioneer in Drug Allergy Research

General Dermatology, Cosmetic laser therapy, Adverse drug reaction

Profile

Wen-Hung Chung graduated from Chung-Shan Medical College, Taiwan in 1997 and obtained his Ph.D. degree from the Taiwan International Graduate Program of Academia Sinica at National Yang Ming University in 2008. He is board certified by the Taiwan Dermatologist Association and is an active member of the American Dematological Society; National Science Council, Taiwan; RegiSCAR consortium.

He has a special interest in adverse drug reactions, Stevens-Johnson Syndrome, toxic epidermal necrolysis and pharmacogenmics. 

For over a decade now, Dr. Chung has devoted his carrier to the research of drug hypersensitivity reactions. His ground-breaking discoveries and techniques have transformed drug hypersensitivity and Stevens-Johnson Syndrome (SJS) care in patients. Some of his major research contributions include:

1. Pinpointing strong genetic correlations between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome (SJS); HLA-B*5801 and allopurinol-severe cutaneous adverse reactions .These important breakthroughs had been published on Nature and Nature Medicine in 2004 and 2008, respectively. 

2. In 2012, Dr. Chung established the first drug hypersensitivity clinical and research center in the nation which receives referral cases of severe drug hypersensitivity from all over Taiwan as well as other countries. Dr. Chung has developed specific techniques to identify culprit drugs for patients with drug hypersensitivity reactions, including patients with anaphylaxis, angioedema, and different delayed types of drug-induced hypersensitivity reactions, such drug hypersensitivity syndrome and SJS. Dr. Chung has also extended his research works for international collaboration with clinical physicians or researchers from France, Germany, Australia, Japan, Singapore, Malaysia, South-Africa, and Mainland China.


Specialty

General Dermatology, Cosmetic laser therapy, Adverse drug reaction

Honors and Awards 

2005         Chen-yuan Lee Young Scientist Medical Research Award

2006         The 2006 Top 10 Rising Stars in Taiwan

2006         Prize of Taiwan Skin Education Research & Development Foundation

2009         Chang Gung Memorial Hospital President Wang’s Golden award

2009         The 7th Y.Z. Hsu Scientific Paper award

2009         Young Investigator Award (Ta-You Wu Memorial Award)

2009         The 47th Ten Outstanding Young Persons, Taiwan

2011         The International League of Dermatological Societies (ILDS) Young Dermatologist International Achievement Award

2014         Outstanding research award of Ministry of Science and Technology

2017         Honorary member of the French Society of Dermatology

2018         2018 Taipei Biotech Award

2018         The 15th National Innovation Award

Major Publications

  1. Chen CH, Chen CB, Chang CJ, Lin YJ, Wang CW, Chi CC, Lu CW, Chen WT, Pan RY, Su SC, Hsu LA, Chang YC, Yu KH, Wu YJ, Lin KM, Hung SI, Chen SM*, Chung WH*. Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population-Based Cohort Study and Meta-Analysis. Clin Pharmacol Ther. 2019 Aug;106(2):391-401. (SCI; IF=6.336)
  2. Pan RY, Chu MT, Wang CW, Lee YS, Lemonnier F, Michels AW, Schutte R, Ostrov DA, Chen CB, Phillips EJ, Mallal SA, Mockenhaupt M, Bellón T, Tassaneeyakul W, White KD, Roujeau JC, Chung WH*, Hung SI*. Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nat Commun. 2019 Aug 8;10(1):3569. (SCI; IF=11.878)
  3. Tsai YG, Liou JH, Hung SI, Chen CB, Chiu TM, Wang CW, Chung WH*. Increased Type 2 Innate Lymphoid Cells in Patients with Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome. J Invest Dermatol. 2019 Aug;139(8):1722-1731. (SCI; IF=6.290)
  4. Chen WT, Wang CW, Lu CW, Chen CB, Lee HE, Hung SI, Choon SE, Yang CH, Liu MT, Chen TJ, Fan WL, Su SC, Lin YY, Chang YC, Chung WH*; Taiwan Severe Cutaneous Adverse Reaction Consortium. The function of HLA-B*13:01 involved in the pathomechanism of dapsone-induced severe cutaneous adverse reactions. J Invest Dermatol. 2018 Jul; 138(7):1546-1554. (SCI; IF=6.287; Dermatology: 2/63)
  5. Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, Chang CJ, Su SC, Hui RC, Chin SW, Huang LF, Lin YY, Chang WY, Fan WL, Yang CY, Ho JC, Chang YC, Lu CW, Chung WH*; Taiwan Severe Cutaneous Adverse Reaction (TSCAR) Consortium. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018 Mar 1;128(3):985-996. (SCI; IF=12.784; Medicine, research & experimental: 4/128).
  6. Lin CY, Wang CW, Hui CR, Chang YC, Yang CH, Cheng CY, Chen WW, Ke WM, Chung WH*. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study. Allergy. 2018 Jan;73(1):221-229. (SCI; IF=7.361; Allergy: 2/23; Immunology: 19/137).
  7. Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, Chosidow O, Valeyrie-Allanore L, Bellon T, Sekula P, Wang CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH*. Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Invest Dermatol. 2017 May;137(5):1065-1073. (SCI; IF=6.915; Dermatology: 1/61)
  8. Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, Sukasem C, Hsu CN, Su SC, Chang WC, Hui RC, Chu CY, Chen YJ, Wu CY, Hsu CK, Chiu TM, Sun PL, Lee HE, Yang CY, Kao PH, Yang CH, Ho HC, Lin JY, Chang YC, Chen MJ, Lu CW, Ng CY, Kuo KL, Lin CY, Yang CS, Chen DP, Chang PY, Wu TL, Lin YJ, Weng YC, Kuo TT, Hung SI, Chung WH*; Taiwan Severe Cutaneous Adverse Reaction Consortium. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology. 2017 Jan 3;88(1):78-86. (SCI; IF=8.166; Clinical Neurology: 8/193)
  9. Ng CY, Yeh YT, Wang CW, Hung SI, Yang CH, Chang YC, Chang WC, Lin YJ, Chang CJ, Su SC, Fan WL, Chen DY, Wu YJ, Tian YC, Hui RC, Chung WH*; Taiwan Severe Cutaneous Adverse Reaction Consortium. Impact of the HLA-B*58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions. J Invest Dermatol. 2016 Jul; 136(7): 1373-81. (SCI; IF=6.915; Dermatology: 1/61)
  10. White KD, Chung WH, Hung SI, Mallal S, Phillips EJ. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. J Allergy Clin Immunol. 2015 Aug;136(2):219-34. (SCI; IF=12.485; Allergy: 1/25; Immunology: 5/151)
  11. Yang CY, Chen CH, Deng ST, Huang CS, Lin YJ, Chen YJ, Wu CY, Hung SI, Chung WH*. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan. JAMA Intern Med. 2015 Sep 1;175(9):1550-7. (SCI; IF=14; Medicine, General & Internal 6/155)
  12. Chung WHPan RYChu MTChin SWHuang YLWang WCChang JYHung SI*. Oxypurinol- Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions. J Invest Dermatol. 2015 May Sep;135(9):2237-2248. (SCI; IF=6.344; Immunology: 20/151; Infectious diseases: 5/83; Microbiology: 14/123)
  13. Chung WH, Chang WC, Stocker SL, Juo CG, Graham GG, Lee MH, Williams KM, Tian YC, Juan KC, Jan Wu YJ, Yang CH, Chang CJ, Lin YJ, Day RO, Hung SI*. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2014 Aug 12. (SCI; IF=12.384; Rheumatology 1/32)
  14. Chung WH*, Chang WC, Lee YS, Wu YY, Yang CH, Ho HC, Chen MJ, Lin JY, Hui RCY, Ho JC, Wu WM, ChenTJ, Wu T, WU YR, Hsih MS, TU PH, Chang CN, Hsu CN, Wu TL, Choon SE, Hsu CK, Chen DY, Liu CS, Lin CY, Kaniwa N, Saito Y, Takahashi Y, Nakamura R, Azukizawa H, SHi Y, Wang TH, Chang SS, Tsai SF, Chang CJ, Chang YS, Hung SI*, Taiwan SCAR consortium, and JPDSC. Genetic variants associated with pheytoin-related severe cutaneous adverse reactions. JAMA. 2014 Aug 6;312(5):525-34. (SCI; IF=37.684; Medicine, General & Internal 3/155)
  15. Lin YF, Yang CH, Sindy H, Lin JY, Rosaline, Hui CY, Tsai YC, Wu TS, Huang CT, Kao KC, Hu HC, Chiu CH, Hung SI, Chung WH*. Severe Cutaneous Adverse Reactions Related to Systemic Antibiotics. Clin Infect Dis. 2014 May;58(10):1377-85. (SCI; IF=8.376; Immunology: 9/151; Infectious diseases: 2/83; Microbiology:10/123)
  16. Wang CW, Chung WH, Cheng YF, Ying NW, Peck K, Chen YT, Hung SI*. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. J Allergy Clin Immunol. 2013 Sep;132(3):713-722. (SCI; IF=12.485; Allergy: 1/25; Immunology: 5/151)
  17. Hung SI, Chung WH*. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology. 2013 Apr 23;80(17):1621-2. Neurology. 2013 Apr 23;80(17):1621. (SCI; IF=8.166; Clinical Neurology: 8/193)
  18. Ko JH, Chung WH*. Serum sickness. Lancet. 2013 Jan 19;381. (SCI; IF=44.022; Medicine, general & internal: 2/155)
  19. Wei CY, Chung WH, Huang HW, Chen YT, Hung SI*. Direct interaction between HLA-B and carbamazepine activates T cells in Stevens-Johnson syndrome. J Allergy Clin Immunol. 2012 Jun;129(6):1562-9. (SCI; IF=12.485; Allergy: 1/25; Immunology: 5/151)
  20. Yang CY, Dao RL, Lee TJ, Lu CW, Yang CH, Hung SI, Chung WH*. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology. 2011 Dec 6;77(23):2025-33. (SCI; IF=8.166; Clinical Neurology: 8/193)
  21. Ko TM, Chung WH, Wei CY, Shih HY, Chen JK, Lin CH, Chen YT, Hung SI*. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 2011 Dec;128(6):1266-1276. (SCI; IF=12.485; Allergy: 1/25; Immunology: 5/151)
  22. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, Tai CT, Wu SL, Lu CH, Hsu YC, Yu HY, Ro LS, Lu CT, Chu CC, Tsai JJ, Su YH, Lan SH, Sung SF, Lin SY, Chuang HP, Huang LC, Chen YJ, Tsai PJ, Liao HT, Lin YH, Chen CH, Chung WH, Hung SI, Wu JY, Chang CF, Chen L, Chen YT*, Shen CY; Taiwan SJS Consortium. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011 Mar 24;364(12):1126-33. (SCI; IF=59.558; Medicine, general & internal: 1/155)
  23. Phillips EJ*, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011 Mar;127:S60-6. (SCI; IF=12.485; Allergy: 1/25; Immunology: 5/151)
  24. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT*. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008 Dec;14(12):1343-50. (SCI; IF=30.357; Biochemistry & molecular biology: 1/289; Cell biology: 2/187; Medicine, research & experimental: 1/124)
  25. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT*. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Nat Acad Sci U S A. 2005; 102(11):4134-9. (SCI; IF=9.809; Multidisciplinary sciences: 4/55)
  26. Chung WH, Hung SI, Hong SH, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT*. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428(6982):486. (SCI; IF=42.351; Multidisciplinary sciences: 1/55)